NMIBC: Clinical Trials

5 not yet recruiting, 2 completed, 2 recruiting. 9 Phase 2, 6 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	9	Not yet recruiting 5, Completed 2, Recruiting 2
Phase 1	6	Not yet recruiting 4, Completed 1, Recruiting 1

Follow NMIBC: new trials by email Literature Review of NMIBC trials Research Report on NMIBC

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer TTP-ICG NIR fluorescent diagnostic agent - NMIBC	Phase 1 / Phase 2	Not yet recruiting	Yunnan Cancer Hospital	30	2026-10-30	2026-09-24
The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG. SPGL008 - NMIBC	Phase 1 / Phase 2	Not yet recruiting	Shenyang Sunshine Pharmaceutical Co., LTD.	120	2026-03-12	2026-03-03
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG Intravesical Recombinant Mycobacterium (rMBCG) - NMIBC	Phase 1 / Phase 2	Recruiting	ImmunityBio, Inc.	40	2025-10-15	2026-03-27
A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. Gemcitabine + BCG, BCG (TICE strain) - NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma	Phase 1 / Phase 2	Not yet recruiting	Queen's University	31	2025-08-01	2025-07-17
SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt SHR-1501+SHR-2005 - NMIBC	Phase 1 / Phase 2	Not yet recruiting	Fudan University	58	2024-10-01	2024-09-19
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. Distitamab Vedotin in combination with Tislelizumab - NMIBC	Phase 2	Not yet recruiting	Fujian Medical University Union Hospital	40	2024-10-01	2024-10-10
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects RC48-ADC in Combination with gemcitabine - NMIBC	Phase 2	Recruiting	RemeGen Co., Ltd.	85	2023-06-08	2023-07-13
A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer VG161 via Intravesical Instillation - NMIBC	Phase 1 / Phase 2	Completed	Ding-Wei Ye	20	2021-10-12	2026-04-01
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors Pemigatinib - Bladder Cancer, NMIBC	Phase 2	Completed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	30	2020-10-02	2025-10-03

Narrower conditions

Non-Muscle Invasive Bladder Neoplasms (9)  ·  Urinary Bladder Neoplasms (2)  ·  Carcinoma, Transitional Cell (1)  ·  Neoplasms (1)

Broader conditions

Carcinoma (9)  ·  Female Urogenital Diseases (9)  ·  Female Urogenital Diseases and Pregnancy Complications (9)  ·  Male Urogenital Diseases (9)  ·  Neoplasms by Histologic Type (9)  ·  Neoplasms by Site (9)  ·  Neoplasms, Glandular and Epithelial (9)  ·  Urinary Bladder Diseases (9)  ·  Urogenital Diseases (9)  ·  Urogenital Neoplasms (9)  ·  Urologic Diseases (9)  ·  Urologic Neoplasms (9)  ·  Neoplasms (8)  ·  Urinary Bladder Neoplasms (7)

Interventions

Gemcitabine (2)  ·  BCG Vaccine (1)  ·  pemigatinib (1)  ·  tislelizumab (1)

Sponsors

Ding-Wei Ye (1)  ·  Fudan University (1)  ·  Fujian Medical University Union Hospital (1)  ·  ImmunityBio, Inc. (1)  ·  Queen's University (1)  ·  RemeGen Co., Ltd. (1)  ·  Shenyang Sunshine Pharmaceutical Co., LTD. (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)  ·  Yunnan Cancer Hospital (1)

Countries

China (5)  ·  United States (2)  ·  Canada (1)

Top investigators

Dingwei Ye, MD (1)  ·  Noah M Hahn, MD (1)